Tempest Therapeutics, Inc.

NASDAQ:TPST

0.91 (USD) • At close November 1, 2024
Bedrijfsnaam Tempest Therapeutics, Inc.
Symbool TPST
Munteenheid USD
Prijs 0.909
Beurswaarde 24,159,029
Dividendpercentage 0%
52-weken bereik 0.88 - 6
Industrie Biotechnology
Sector Healthcare
CEO Mr. Stephen R. Brady J.D., LLM
Website https://www.tempesttx.com

An error occurred while fetching data.

Over Tempest Therapeutics, Inc.

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist

Vergelijkbare Aandelen

AVROBIO, Inc. logo

AVROBIO, Inc.

AVRO

1.4 USD

Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.

TERN

6.94 USD

Biomerica, Inc. logo

Biomerica, Inc.

BMRA

0.372 USD

Oncternal Therapeutics, Inc. logo

Oncternal Therapeutics, Inc.

ONCT

1.5 USD

Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.

CRBP

16.92 USD

Evogene Ltd. logo

Evogene Ltd.

EVGN

2.24 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)